What is Experic?
Experic operates as a comprehensive CDMO, offering services that span every phase of a product's life cycle. The company specializes in manufacturing across a variety of dosage forms, including tablets, pellets, capsules, and low-dose dry powder inhalation. Operating from a state-of-the-art, Class A cGMP facility, Experic is equipped to manage global delivery of high-quality pharmaceutical products, even for expedited projects. Their commitment extends to providing unparalleled knowledge, expertise, and customer service, positioning them as a key partner in drug development and manufacturing.
How much funding has Experic raised?
Experic has raised a total of $14.2M across 2 funding rounds:
Debt
$150K
Series B
$14M
Debt (2020): $150K with participation from PPP
Series B (2022): $14M led by East Seattle Partners and Harro Höfliger
Key Investors in Experic
East Seattle Partners
East Seattle Partners is a multi-asset investment firm specializing in growth equity and real estate investments, founded by Alan Frazier. The firm focuses on investing in growth companies that aim to redefine business categories and address market challenges, as well as in the renovation of historically significant real estate properties. With a commitment to creating lasting impact, East Seattle Partners provides capital, resources, and expertise to help companies become market leaders while enhancing community value. Their experienced team emphasizes strategic thinking and partnership in every investment endeavor.
Harro Höfliger
Harro Höfliger is a key player in the pharmaceutical manufacturing equipment sector, known for its innovative solutions in processing and packaging. Their involvement suggests a strategic alignment with Experic's manufacturing capabilities and a potential for synergistic growth in the pharmaceutical supply chain.
What's next for Experic?
With the infusion of major enterprise-level funding, Experic is poised for significant expansion and enhancement of its operational capabilities. The recent capital injection, following a Series B round, suggests a strategic focus on scaling production capacity, advancing technological infrastructure, and potentially broadening its service offerings. This financial backing will likely enable Experic to further solidify its market position, cater to an increasing demand for complex pharmaceutical manufacturing, and accelerate its support for clients navigating the intricate path from clinical trials to commercial market launch. The company's trajectory indicates a strong emphasis on growth and innovation within the pharmaceutical supply chain.
See full Experic company page
